4P-Pharma is a clinical stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases.

They aim to evaluate innovative programs with strong scientific rationale, sourced from the top academic research labs and AI tech companies.

Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, their key differentiation is their dual leverage of in-house R&D capabilities located within the Pasteur Institute of Lille, combined with Single Product Vehicle (SPV)-based deployment in charge of advancing the assets through accelerated clinical development to market approvals and distribution agreements by geographic and therapeutic area.

Since 2014, the team has reviewed more than 400 projects from different sources of innovation, more then 30 entered in their laboratories for a technical due diligence and 2 have been selected for clinical development.

Two SPVs have been launched:

–  4Living Biotech dedicated to the clinical development of 4P021, a first-in-class treatment for acute respiratory distress syndrome (ARDS) and pulmonary complications.

–  4Moving Biotech dedicated to the clinical development of 4P004, a first-in-class disease modifying treatment for osteoarthritis.

–  Therapeutic areas: Chronic and autoimmune diseases, Respiratory and infectious diseases, Preventive therapies, Ophtalmological diseases

–  Based in: Lille & Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2014